Review
  • Development of Hemoglobin-based Oxygen Delivery System Using PEGylation

  • Hyemin Cho*, Kidong Kim*, Jaeeun Oh*, Young-Joon Park**, and Sejin Son*, ***,†

  • *Department of Biological Sciences and Bioengineering, Inha University, Incheon22212, Korea
    **College of Pharmacy, Ajou University, 206, World Cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Korea
    ***Department of Biological Sciences, Inha University, Incheon 22212, Korea

  • 페길화를 이용한 헤모글로빈 기반 산소 전달 시스템 개발

  • 조혜민* · 김기동* · 오재은* · 박영준** · 손세진*, ***,†

  • *인하대학교 바이오시스템융합학과, **아주대학교 약학대학, ***인하대학교 생명과학과

  • Reproduction, stored in a retrieval system, or transmitted in any form of any part of this publication is permitted only by written permission from the Polymer Society of Korea.

References
  • 1. Cao, M.; Zhao, Y.; He, H.; Yue, R.; Pan, L.; Hu, H.; Ren, Y.; Qin, Q.; Yi, X.; Yin, T. New Applications of HBOC-201: a 25-year Review of the Literature. Front Med 2021, 8, 794561.
  •  
  • 2. Alayash, A. I. Hemoglobin-based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm Than Help? Biomolecules 2017, 7, 2.
  •  
  • 3. Chung, S.; Nguyen, T.; Wollocko, H.; Daneshvar, M. 559: Effectiveness of OxyVita Novel Hemoglobin-Based Oxygen Carrier (HBOC) in Treatment of CO Poisoning. Crit. Care Med 2021, 49, 272.
  •  
  • 4. Chen, L.; Yang, Z.; Liu, H. Hemoglobin-based Oxygen Carriers: Where are We Now in 2023? Medicina 2023, 59, 396.
  •  
  • 5. Gupta, A. S. Hemoglobin-based Oxygen Carriers: Current State-of-the-art and Novel Molecules. Shock 2019, 52, 70-83.
  •  
  • 6. Yu, S. Hemoglobin: Physiology and Hemoglobinopathy. In Blood Substitutes and Oxygen Biotherapeutics;Henry Liu, Alan D. Kaye, Jonathan S. Jahr;Springer: Pennsylvania, 2022; pp 45-51.
  •  
  • 7. Gulati, A.; Barve, A.; Sen, A. P. Pharmacology of Hemoglobin Therapeutics. J. Clin. Lab. Med. 1999, 133, 112-119.
  •  
  • 8. Vandegriff, K. D.; Winslow, R. M. Hemospan: Design Principles for a New Class of Oxygen Therapeutic. Artif. Organs. 2009, 33, 133-138.
  •  
  • 9. Cooper, C. E.; Bird, M.; Sheng, X.; Choi, J.-W.; Silkstone, G. G.; Simons, M.; Syrett, N.; Piano, R.; Ronda, L.; Bettati, S. Stability of Maleimide-PEG and Mono-sulfone-PEG Conjugation to a Novel Engineered Cysteine in the Human Hemoglobin Alpha Subunit. Front. Chem. 2021, 9, 707797.
  •  
  • 10. Priavalle, C.; De Angelo, J. Hemoximer: History, Pharmacology, Pre-Clinical Studies, Clinical Trials, and Lessons Learned. In Blood Substitutes and Oxygen Biotherapeutics; Henry Liu, Alan D. Kaye, Jonathan S. Jahr;Springer: Pennsylvania, 2022; pp 375-382.
  •  
  • 11. Estep, T. N. HemAssist: development, clinical trials, lessons learned. In Blood Substitutes and Oxygen Biotherapeutics;Henry Liu, Alan D. Kaye, Jonathan S. Jahr;Springer: Pennsylvania, 2022; pp 287-292.
  •  
  • 12. Harris, D. R.; Palmer, A. F. Modern Cross-linking Strategies for Synthesizing Acellular Hemoglobin-based Oxygen Carriers. Biotechnol. Prog. 2008, 24, 1215-1225.
  •  
  • 13. Prempeh, A. B.; Cheng, D. C. O-Raffinose Cross-Linked Human Hemoglobin (Hemolink): History, Clinical Trials and Lessons Learned. In Blood Substitutes and Oxygen Biotherapeutics; Henry Liu, Alan D. Kaye, Jonathan S. Jahr;Springer: Pennsylvania, 2022; pp 305-312.
  •  
  • 14. Moore, E. E.; Moore, F. A.; Fabian, T. C.; Bernard, A. C.; Fulda, G. J.; Hoyt, D. B.; Duane, T. M.; Weireter Jr, L. J.; Gomez, G. A.; Cipolle, M. D. Human Polymerized Hemoglobin for the Treatment of Hemorrhagic Shock When Blood is Unavailable: the USA Multicenter Trial. J. Am. Coll. Surg. 2009, 208, 1-13.
  •  
  • 15. Jahr, J. S.; Moallempour, M.; Lim, J. C. HBOC-201, Hemoglobin Glutamer-250 (bovine), Hemopure® (Biopure Corporation). Expert Opin. Biol. Ther. 2008, 8, 1425-1433.
  •  
  • 16. Rudolph, A. S. Encapsulated Hemoglobin: Current Issues and Future Goals. Artif. Cells. Nanomed Biotechnol. 1994, 22, 347-360.
  •  
  • 17. Kaneda, S.; Ishizuka, T.; Goto, H.; Kimura, T.; Inaba, K.; Kasukawa, H. Liposome-encapsulated Hemoglobin, TRM-645: Current Status of the Development and Important Issues for Clinical Application. Artif. Organs. 2009, 33, 146-152.
  •  
  • 18. Harris, J. M.; Chess, R. B. Effect of Pegylation on Pharmaceuticals. Nat. Rev. Drug. Discov. 2003, 2, 214-221.
  •  
  • 19. Ekladious, I.; Colson, Y. L.; Grinstaff, M. W. Polymer–drug Conjugate Therapeutics: Advances, Insights and Prospects. Nat. Rev. Drug. Discov. 2019, 18, 273-294.
  •  
  • 20. Cherian, V. T. Physiological Functions of Blood. In Blood Substitutes and Oxygen Biotherapeutics; Henry Liu, Alan D. Kaye, Jonathan S. Jahr;Springer: Pennsylvania, 2022; pp 33-43.
  •  
  • 21. Bunn, H. F.; Forget, B. G. Hemoglobin-molecular, Genetic, and Clinical Aspects; 1986.
  •  
  • 22. Alayash, A. I. Hemoglobin-based Blood Substitutes: Oxygen Carriers, Pressor Agents, or Oxidants? Nat. Biotechnol. 1999, 17, 545-549.
  •  
  • 23. Klotz, I. M. Hemoglobin–oxygen Equilibria: Retrospective and Phenomenological Perspective. Biophys Chem. 2002, 100, 123-129.
  •  
  • 24. Goutelle, S.; Maurin, M.; Rougier, F.; Barbaut, X.; Bourguignon, L.; Ducher, M.; Maire, P. The Hill Equation: a Review of Its Capabilities in Pharmacological Modelling. Fundam Clin. Pharmacol. 2008, 22, 633-648.
  •  
  • 25. Henry Liu, Alan D. Kaye, Jonathan S. Jahr; In Blood Substitutes and Oxygen Biotherapeutics; Springer: Pennsylvania, 2022.
  •  
  • 26. Umbreit, J. Methemoglobin—it's Not Just Blue: a Concise Review. Am. J. Hematol. 2007, 82, 134-144.
  •  
  • 27. Tellone, E.; Barreca, D.; Russo, A.; Galtieri, A.; Ficarra, S. New Role for An Old Molecule: The 2, 3-diphosphoglycerate Case. Biochim. Biophys Acta. Gen. Subj. 2019, 1863, 1602-1607.
  •  
  • 28. Campbell-Lee, S. A.; Ness, P. M. Packed Red Blood Cells and Related Products. Blood Banking and Transfusion Medicine: Basic Principles and Practice: Second Edition; Christopher D. Hillyer, Leslie E. Silberstein, Paul M. Ness, Kenneth C. Anderson, John D. Roback; Elsevier: Philadelphia, 2006; pp 250-258.
  •  
  • 29. Vaughn, M. W.; Kuo, L.; Liao, J. C. Effective Diffusion Distance of Nitric Oxide in the Microcirculation. Am. J. Physiol. Heart Circ. Physiol. 1998, 274, H1705-H1714.
  •  
  • 30. Liu, C.; Liu, X.; Janes, J.; Stapley, R.; Patel, R. P.; Gladwin, M. T.; Kim-Shapiro, D. B. Mechanism of Faster NO Scavenging by Older Stored Red Blood Cells. Redox. Biol. 2014, 2, 211-219.
  •  
  • 31. Vaughn, M. W.; Huang, K.-T.; Kuo, L.; Liao, J. C. Erythrocytes Possess An Intrinsic Barrier to Nitric Oxide Consumption. J. Biol. Chem. 2000, 275, 2342-2348.
  •  
  • 32. Vaughn, M. W.; Huang, K.-T.; Kuo, L.; Liao, J. C. Erythrocyte Consumption of Nitric Oxide: Competition Experiment and Model Analysis. Nitric. Oxide. 2001, 5, 18-31.
  •  
  • 33. Butler, A. R.; Megson, I. L.; Wright, P. G. Diffusion of Nitric Oxide and Scavenging by Blood in the Vasculature Biochim Biophys Acta. Gen. Sub. 1998, 1425, 168-176.
  •  
  • 34. Liao, J. C.; W. Hein, T.; Vaughn, M. W.; Huang, K.-T.; Kuo, L. Intravascular Flow Decreases Erythrocyte Consumption of Nitric Oxide. Proc. Natl. Acad. Sci. 1999, 96, 8757-8761.
  •  
  • 35. Vallelian, F.; Buehler, P. W.; Schaer, D. J. Hemolysis, Free Hemoglobin Toxicity, and Scavenger Protein Therapeutics. Blood. Adv. 2022, 140, 1837-1844.
  •  
  • 36. Deuel, J. W.; Schaer, C. A.; Boretti, F. S.; Opitz, L.; García-Rubio, I.; Baek, J.; Spahn, D. R.; Buehler, P. W.; Schaer, D. J. Hemoglobinuria-Related Acute Kidney Injury is Driven by Intrarenal Oxidative Reactions Triggering a Heme Toxicity Response. Cell. Death. Dis. 2016, 7, e2064-e2064.
  •  
  • 37. Baek, J. H.; Yalamanoglu, A.; Gao, Y.; Guenster, R.; Spahn, D. R.; Schaer, D. J.; Buehler, P. W. Iron Accelerates Hemoglobin Oxidation Increasing Mortality in Vascular Diseased Guinea Pigs Following Transfusion of Stored Blood. JCI. Insight. 2017, 2.
  •  
  • 38. Bunn, H. F.; Jandl, J. Exchange of Heme Among Hemoglobins and Between Hemoglobin and Albumin. J. Biol. Chem. 1968, 243, 465-475.
  •  
  • 39. Belcher, J. D.; Chen, C.; Nguyen, J.; Milbauer, L.; Abdulla, F.; Alayash, A. I.; Smith, A.; Nath, K. A.; Hebbel, R. P.; Vercellotti, G. M. Heme Triggers TLR4 Signaling Leading to Endothelial Cell Activation and Vaso-occlusion in Murine Sickle Cell Disease. Blood. Adv. 2014, 123, 377-390.
  •  
  • 40. Pfefferlé, M.; Ingoglia, G.; Schaer, C. A.; Yalamanoglu, A.; Buzzi, R.; Dubach, I. L.; Tan, G.; López-Cano, E. Y.; Schulthess, N.; Hansen, K. Hemolysis Transforms Liver Macrophages Into Antiinflammatory Erythrophagocytes. J. Clin. Invest. 2020, 130, 5576-5590.
  •  
  • 41. Martins, R.; Maier, J.; Gorki, A.-D.; Huber, K. V.; Sharif, O.; Starkl, P.; Saluzzo, S.; Quattrone, F.; Gawish, R.; Lakovits, K. Heme Drives Hemolysis-induced Susceptibility to Infection via Disruption of Phagocyte Functions. Nat. Immunol. 2016, 17, 1361-1372.
  •  
  • 42. Oesterhelt, F.; Rief, M.; Gaub, H. Single Molecule Force Spectroscopy by AFM Indicates Helical Structure of Poly(ethylene-glycol) in Water. New. J. Phys. 1999, 1, 6.
  •  
  • 43. Ibrahim, M.; Ramadan, E.; Elsadek, N. E.; Emam, S. E.; Shimizu, T.; Ando, H.; Ishima, Y.; Elgarhy, O. H.; Sarhan, H. A.; Hussein, A. K. Polyethylene Glycol (PEG): The Nature, Immunogenicity, and Role in the Hypersensitivity of PEGylated Products. J. Control. Release. 2022, 351, 215-230.
  •  
  • 44. Chen, B.-M.; Cheng, T.-L.; Roffler, S. R. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-polyethylene Glycol Antibodies. ACS Nano. 2021, 15, 14022-14048.
  •  
  • 45. P Garay, R.; P Labaune, J. Immunogenicity of Polyethylene Glycol (PEG). Open. Conf. Proc. J. 2011; Vol. 2.
  •  
  • 46. d'Avanzo, N.; Celia, C.; Barone, A.; Carafa, M.; Di Marzio, L.; Santos, H. A.; Fresta, M. Immunogenicity of Polyethylene Glycol-based Nanomedicines: Mechanisms, Clinical Implications and Systematic Approach. Adv. Ther. 2020, 3, 1900170.
  •  
  • 47. Wan, X.; Zhang, J.; Yu, W.; Shen, L.; Ji, S.; Hu, T. Effect of Protein Immunogenicity and PEG Size and Branching on the Anti-PEG Immune Response to PEGylated Proteins. Process Biochem. 2017, 52, 183-191.
  •  
  • 48. Zhai, Y.; Zhao, Y.; Lei, J.; Su, Z.; Ma, G. Enhanced Circulation Half-life of Site-specific PEGylated rhG-CSF: Optimization of PEG Molecular Weight. J. Biotech. 2009, 142, 259-266.
  •  
  • 49. Turecek, P. L.; Bossard, M. J.; Schoetens, F.; Ivens, I. A. PEGylation of Biopharmaceuticals: a Review of Chemistry and Nonclinical Safety Information of Approved Drugs. J. Pharm. Sci.2016, 105, 460-475.
  •  
  • 50. Zhou, Y.; Kopeček, J. Biological Rationale for the Design of Polymeric Anti-cancer Nanomedicines. J. Drug. Target. 2013, 21, 1-26.
  •  
  • 51. Lundberg, P.; Lee, B. F.; van den Berg, S. A.; Pressly, E. D.; Lee, A.; Hawker, C. J.; Lynd, N. A. Poly[(ethylene oxide)-co-(methylene ethylene oxide)]: A Hydrolytically Degradable Poly(ethylene oxide) Platform. ACS Macro. Lett. 2012, 1, 1240-1243.
  •  
  • 52. Roberts, M.; Bentley, M.; Harris, J. Chemistry for Peptide and Protein PEGylation. Adv. Drug. Deliv Rev. 2002, 54, 459-476.
  •  
  • 53. Milla, P.; Dosio, F.; Cattel, L. PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery. Curr. Drug. Metab. 2012, 13, 105-119.
  •  
  • 54. Kozlowski, A.; Harris, J. M. Improvements in Protein PEGylation: Pegylated Interferons for Treatment of Hepatitis C. J. Control. Release. 2001, 72, 217-224.
  •  
  • 55. Kozlowski, A.; Charles, S. A.; Harris, J. M. Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C. Bio. Drugs. 2001, 15, 419-429.
  •  
  • 56. Veronese, F. M.; Pasut, G. PEGylation, Successful Approach to Drug Delivery. Drug. Discov. Today. 2005, 10, 1451-1458.
  •  
  • 57. Gupta, V.; Bhavanasi, S.; Quadir, M.; Singh, K.; Ghosh, G.; Vasamreddy, K.; Ghosh, A.; Siahaan, T. J.; Banerjee, S.; Banerjee, S. K. Protein PEGylation for Cancer Therapy: Bench to Bedside. J. Cell. Commun. Signal. 2019, 13, 319-330.
  •  
  • 58. Knoff, D. S.; Kim, S.; Fajardo Cortes, K. A.; Rivera, J.; Cathey, M. V.; Altamirano, D.; Camp, C.; Kim, M. Non-Covalently Associated Streptavidin Multi-Arm Nanohubs Exhibit Mechanical and Thermal Stability in Cross-Linked Protein-Network Materials. Biomacromolecules 2022, 23, 4130-4140.
  •  
  • 59. Kono, H. Characterization and Properties of Carboxymethyl Cellulose Hydrogels Crosslinked by Polyethylene Glycol. Carbohydr. Polym. 2014, 106, 84-93.
  •  
  • 60. Kamaraj, M.; Sreevani, G.; Prabusankar, G.; Rath, S. N. Mechanically Tunable Photo-cross-linkable Bioinks for Osteogenic Differentiation of MSCs in 3D Bioprinted Constructs. Mater. Sci. Eng. C 2021, 131, 112478.
  •  
  • 61. Li, X.; Ding, J.; Zhang, Z.; Yang, M.; Yu, J.; Wang, J.; Chang, F.; Chen, X. Kartogenin-incorporated Thermogel Supports Stem Cells for Significant Cartilage Regeneration. ACS Appl. Mater. Interfaces 2016, 8, 5148-5159.
  •  
  • 62. Harris, J. M.; Martin, N. E.; Modi, M. Pegylation: a Novel Process for Modifying Pharmacokinetics. Clin. Pharmacokinet. 2001, 40, 539-551.
  •  
  • 63. Chang, T. M. S. Blood Substitutes Based on Nanobiotechnology. Trends. Biotechnol. 2006, 24, 372-377.
  •  
  • 64. Stowell, C. P.; Levin, J.; Spiess, B. D.; Winslow, R. M. Progress in the Development of RBC Substitutes. Transfusion 2001, 41, 287-299.
  •  
  • 65. Winslow, R. M. Cell-free Oxygen Carriers: Scientific Foundations, Clinical Development, and New Directions. Biochim Biophys Acta Proteins Proteom 2008, 1784, 1382-1386.
  •  
  • 66. Alayash, A. I. Setbacks in Blood Substitutes Research and Development: a Biochemical Perspective. Clin. Lab. Med. 2010, 30, 381-389.
  •  
  • 67. Buehler, P. W.; D’Agnillo, F.; Schaer, D. J. Hemoglobin-based Oxygen Carriers: from Mechanisms of Toxicity and Clearance to Rational Drug Design. Trends. Mol. Med. 2010, 16, 447-457.
  •  
  • 68. Smani, Y. Hemospan: a Hemoglobin-based Oxygen Carrier for Potential Use as a Blood Substitute and for the Potential Treatment of Critical Limb Ischemia. Curr Opin Investig Drugs 2008, 9, 1009-1019.
  •  
  • 69. Plastini, T.; Locantore-Ford, P.; Bergmann, H. Sanguinate: a Novel Blood Substitute Product. Blood. 2017, 130, 1120.
  •  
  • 70. Romito, B. T.; Romito, J. W.; Abuchowski, A. Sanguinate: History and Clinical Evaluation of a Multimodal HBOCs. In Blood Substitutes and Oxygen Biotherapeutics; Henry Liu, Alan D. Kaye, Jonathan S. Jahr;Springer: Pennsylvania, 2022; pp 335-343.
  •  
  • 71. Sakai, H.; Sou, K.; Tsuchida, E. Hemoglobin-vesicles as An Artificial Oxygen Carrier. Methods Enzymol 2009, 465, 363-384.
  •  
  • 72. Sakai, H.; Takeoka, S.; Park, S. I.; Kose, T.; Nishide, H.; Izumi, Y.; Yoshizu, A.; Kobayashi, K.; Tsuchida, E. Surface Modification of Hemoglobin Vesicles with Poly(ethylene glycol) and Effects on Aggregation, Viscosity, and Blood Flow During 90 Exchange Transfusion in Anesthetized Rats. Bioconjug Chem 1997, 8, 23-30.
  •  
  • 73. Matsuhira, T.; Sakai, H. Artificial Oxygen Carriers, from Nanometer-to Micrometer-sized Particles, Made of Hemoglobin Composites Substituting for Red Blood Cells. Particuology 2022, 64, 43-55.
  •  
  • Polymer(Korea) 폴리머
  • Frequency : Bimonthly(odd)
    ISSN 0379-153X(Print)
    ISSN 2234-8077(Online)
    Abbr. Polym. Korea
  • 2023 Impact Factor : 0.4
  • Indexed in SCIE

This Article

  • 2024; 48(5): 449-459

    Published online Sep 25, 2024

  • 10.7317/pk.2024.48.5.449
  • Received on Jul 3, 2024
  • Revised on Aug 27, 2024
  • Accepted on Aug 27, 2024

Correspondence to

  • and Sejin Son

  • *Department of Biological Sciences and Bioengineering, Inha University, Incheon22212, Korea
    ***Department of Biological Sciences, Inha University, Incheon 22212, Korea

  • E-mail: ssejin@inha.ac.kr